Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population

Dimachkie MM, Barohn RJ, Amato A (2014) Idiopathic inflammatory myopathies. Neurol Clin 32:595–628

Betteridge Z, McHugh N (2016) Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 280:8–23

You H et al (2022) Time-dependent changes in RPILD and mortality risk in anti-MDA5+ DM patients: a cohort study of 272 cases in China. Rheumatology keac450. https://doi.org/10.1093/rheumatology/keac450

Gupta L, Naveen R, Gaur P, Agarwal V, Aggarwal R (2021) Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis. Semin Arthritis Rheum 51:113–120

Zhong L, Yu Z, Song H (2019) Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: a meta-analysis of 20 cohorts. Clin Immunol Orlando Fla 198:11–18

Albayda J et al (2017) Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res 69:1771–1776

Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN et al (2013) The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine 92:223–243

Bottai M et al (2017) EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open 3:e000507

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347

Montagnese F, Babačić H, Eichhorn P, Schoser B (2019) Evaluating the diagnostic utility of new line immunoassays for myositis antibodies in clinical practice: a retrospective study. J Neurol 266:1358–1366

Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, Tincani A, Ross SJ, Chan JY, Pauley BA, Chan EK, Satoh M (2012) Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 14(2):R97

Nair AM et al (2021) Mycophenolate in idiopathic inflammatory myositis: outcome data of a large South Asian cohort. Clin Rheumatol 40:2805–2819

Padiyar S, Nair AM, Yadav B, Manikuppam P, Jha A, Manwatkar AA et al (2023) Clinical characteristics, therapeutics, and treatment outcomes of adult patients with anti-melanoma differentiation-associated gene 5 dermatomyositis: a single-center experience from South India. Indian J Rheumatol 18(3):205–211

Aguilar-Vazquez A et al (2021) Geographical latitude remains as an important factor for the prevalence of some myositis autoantibodies: a systematic review. Front Immunol 12:672008

Ichimura Y et al (2021) Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash. Rheumatol Oxf Engl keab518. https://doi.org/10.1093/rheumatology/keab518

Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF (2017) Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res 69:1909–1914

Ichimura Y et al (2012) Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 71:710–713

Loarce-Martos J et al (2021) Clinical characteristics of juvenile idiopathic inflammatory myopathy and comparison with adult patients: analysis from a multicentric cohort in Spain. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. https://doi.org/10.1097/RHU.0000000000001696

Pinotti CS, Cannon L, Dvergsten JA, Wu EY (2023) Calcinosis in juvenile dermatomyositis: updates on pathogenesis and treatment. Front Med 10:1155839

Davuluri S, Duvvuri B, Lood C, Faghihi-Kashani S, Chung L (2022) Calcinosis in dermatomyositis: origins and possible therapeutic avenues. Best Pract Res Clin Rheumatol 36:101768